Metamistad

Metamizole Sodium Monohydrate, the active ingredient in Metamistad, is a pyrazolone analgesic presented as an oral formulation for oral use. It is employed to relieve pain and reduce fever in adult patients.

GNH USA supplies Metamistad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metamistad is a pyrazolone analgesic that acts on pain‑related and febrile pathways. - Pain: provides relief of moderate to severe acute pain. - Fever: reduces elevated body temperature in febrile states. - Postoperative pain: helps control pain after surgical procedures. - Colic: alleviates visceral pain associated with intestinal colic.

Metamistad may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Vomiting: occasional emesis after dosing. - Dizziness: transient light‑headedness. - Hypotension: occasional drop in blood pressure, especially with rapid IV administration. - Rash: mild skin erythema or itching.

Serious or Rare Side Effects: - Agranulocytosis: severe drop in white blood cells, requiring immediate medical attention. - Anaphylaxis: life‑threatening allergic reaction with airway compromise. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic failure: rare liver injury presenting with jaundice and elevated enzymes. - Blood dyscrasias: aplastic anemia or pancytopenia.

Before prescribing Metamistad, clinicians should consider several safety aspects. - Renal impairment: adjust use in patients with reduced kidney function. - Hepatic disease: monitor liver enzymes in patients with liver disorders. - Hematologic monitoring: perform regular blood counts to detect early agranulocytosis. - Concomitant NSAIDs: avoid combined use to reduce risk of gastrointestinal bleeding. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Metamistad can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Warfarin: may potentiate anticoagulant effect, increasing bleeding risk. - Other NSAIDs: combined use raises risk of gastrointestinal ulceration and bleeding.

Moderate Interactions (Monitor Closely): - Antihypertensives: additive hypotensive effect may require dose adjustment. - Diuretics: concurrent use can enhance renal electrolyte disturbances. - Immunosuppressants: may increase risk of hematologic toxicity; monitor blood counts closely.